Add time:08/17/2019         Source:sciencedirect.com

BackgroundGraft vessel disease, the major limitation for long-term success after heart transplantation, is triggered by injury to the graft vessel endothelium, resulting in the expression of adhesion molecules, the migration of leukocytes into the graft, and the release of growth factors. angiopeptin (cas 113294-82-9), a stable analog of somatostatin, is a growth-hormone inhibitor with additional anti-proliferative effects. We evaluated angiopeptin for prevention of graft vasculopathy after cardiac transplantation in the first prospective, randomized, double-blind, clinical trial.

We also recommend Trading Suppliers and Manufacturers of angiopeptin (cas 113294-82-9). Pls Click Website Link as below: cas 113294-82-9 suppliers